Form 4: Sarepta Therapeutics Executive Dallan Murray Reports Stock Transactions

Chief Customer Officer Dallan Murray of Sarepta Therapeutics reports stock transactions including vesting of performance stock units, tax-related sales, and grant of restricted stock units and stock options.

Summary

• Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 7, 2025, 5,500 shares vested under a performance stock unit (PSU) award granted on March 7, 2022.
• On March 10, 2025, 996 shares were sold to cover tax obligations related to restricted stock units vesting at a price of $100.13.
• An additional 2,737 shares were sold on March 10, 2025, at $100.13 to cover tax obligations related to the vesting of PSUs.
• Murray was granted 8,276 restricted stock units (RSUs) on March 10, 2025, which vest 25% annually over four years.
• Murray was also granted stock options to purchase 16,644 shares on March 10, 2025, at an exercise price of $99.69, vesting monthly over four years starting March 10, 2026.
• Following these transactions, Murray directly owns 38,202 shares of common stock and 16,644 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, suggesting a neutral to slightly positive sentiment as it indicates continued alignment of management with company performance.

Positives

• The vesting of performance stock units suggests the company achieved certain performance milestones.
• The grant of restricted stock units and stock options aligns Murray's interests with those of the shareholders.

Future Outlook

The vesting schedule of the RSUs and stock options suggests a long-term commitment by the executive to the company's success.

Industry Context

Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry to incentivize performance and retain talent.
• Vesting schedules of four years for RSUs and options are typical in the industry, aligning executive interests with long-term shareholder value.

Stakeholder Impact

• The vesting of equity awards can be seen positively by shareholders as it aligns management's interests with the company's long-term performance.
• Tax-related sales of shares may have a minor impact on the stock price, but are generally viewed as routine.

Key Dates